David Jin - Avenue Therapeutics COO CFO
| ATXI Stock | USD 2.04 0.04 1.92% |
Insider
David Jin is COO CFO of Avenue Therapeutics
| Age | 34 |
| Address | 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 |
| Phone | 781 652 4500 |
| Web | https://www.avenuetx.com |
David Jin Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Jin against Avenue Therapeutics stock is an integral part of due diligence when investing in Avenue Therapeutics. David Jin insider activity provides valuable insight into whether Avenue Therapeutics is net buyers or sellers over its current business cycle. Note, Avenue Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avenue Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Jin few days ago Acquisition by David Jin of 250000 shares of Avenue Therapeutics at 1.14 subject to Rule 16b-3 | ||
David Jin over six months ago Acquisition by David Jin of 5000 shares of Fortress Biotech at 0.56 subject to Rule 16b-3 | ||
David Jin over six months ago Disposition of tradable shares by David Jin of Fortress Biotech subject to Rule 16b-3 | ||
David Jin over six months ago Acquisition by David Jin of 2352 shares of Fortress Biotech at 1.7 subject to Rule 16b-3 |
Avenue Therapeutics Management Efficiency
The company has return on total asset (ROA) of (2.0135) % which means that it has lost $2.0135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.351) %, meaning that it created substantial loss on money invested by shareholders. Avenue Therapeutics' management efficiency ratios could be used to measure how well Avenue Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -5.89. The Avenue Therapeutics' current Return On Capital Employed is estimated to increase to -21.12. The Avenue Therapeutics' current Other Current Assets is estimated to increase to about 129.6 K, while Total Assets are projected to decrease to under 1.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| James Rolke | Revelation Biosciences | 55 | |
| Frank Kondrad | Neurobo Pharmaceuticals | N/A | |
| Ronald Dundore | Windtree Therapeutics | 69 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Jane Springer | Hoth Therapeutics | 39 | |
| James Foster | Virax Biolabs Group | 39 | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Diane Esq | Windtree Therapeutics | 55 | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| David Briones | Hoth Therapeutics | 48 | |
| Joan Brown | Allarity Therapeutics | 70 | |
| Stefanie Johns | Hoth Therapeutics | 39 | |
| Tracy Rarick | Windtree Therapeutics | N/A | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Robert McRae | Palisade Bio | N/A | |
| John CPA | Windtree Therapeutics | 60 | |
Management Performance
| Return On Equity | -5.35 | ||||
| Return On Asset | -2.01 |
Avenue Therapeutics Leadership Team
Elected by the shareholders, the Avenue Therapeutics' board of directors comprises two types of representatives: Avenue Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avenue. The board's role is to monitor Avenue Therapeutics' management team and ensure that shareholders' interests are well served. Avenue Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avenue Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lindsay Rosenwald, Executive Director | ||
| Xiaoqin MD, Consultant | ||
| Alexandra MD, Chief Officer | ||
| Srinivas Subramanian, Executive President | ||
| David Jin, COO CFO |
Avenue Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avenue Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.35 | ||||
| Return On Asset | -2.01 | ||||
| Current Valuation | 1.3 M | ||||
| Shares Outstanding | 1.91 M | ||||
| Shares Owned By Insiders | 9.85 % | ||||
| Shares Owned By Institutions | 10.33 % | ||||
| Number Of Shares Shorted | 50.92 K | ||||
| Price To Earning | (10.52) X | ||||
| Price To Book | 1.49 X | ||||
| EBITDA | 4.05 M |
Currently Active Assets on Macroaxis
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avenue Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.